Paladin Labs Inc.
MarketLine (a Datamonitor Company)
26 Nov 2013
Available for Immediate Download
Paladin Labs Inc. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Paladin Labs Inc. required for business and competitor intelligence needs - Intelligence on Paladin Labs Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Paladin Labs Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Paladin Labs (Paladin) is a specialty pharmaceutical company focused on developing, acquiring, in-licensing, marketing and distributing pharmaceutical products. The company specializes in the areas of urology, endocrinology, dermatology, pain/central nervous system and women's health. The company primarily operates in Canada, where it is headquartered in Quebec, Canada and employs around 84 people. The company recorded revenues of C$128 million (approximately $124.3 million) in the fiscal year ended December 2010, an increase of 16.7% over 2009. The company's operating profit was C$31.4 million (approximately $30.5 million) in fiscal 2010, a decrease of 18.1% compared to 2009. Its net profit was C$29.7 million (approximately $28.9 million) in fiscal 2010, a decrease of 21.2% compared to 2009. Reasons to Purchase: - Gain understanding of Paladin Labs Inc. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Paladin Labs Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Paladin Labs Inc. your competitors' business structure, strategy and prospects